Cipla to sell Lilly’s Trulicity, Humalog diabetes treatments in India

Published by

BENGALURU (Reuters) – India’s Cipla has signed a deal with Eli Lilly to sell and distribute two of the U.S. drugmaker’s best-selling diabetes treatments in the country, the companies said in a joint statement on Monday. Lilly will transfer its rights in India to sell, promote and distribute its Trulicity and Humalog products, while continuing to maintain its existing operating model for the remaining portfolio of its products, the companies said. The deal will allow Cipla to expand access to the drugs in the country with the second-highest number of diabetic people in the world. India has more…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *